October 2024

Contents

Special reports

• HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care

• Major update of UK PrEP guidelines online for public consultation

Conference reports

• HIVR4P 2024: Introduction

• Urgency of planning broad vaccine-like access to lenacapavir PrEP globally

• Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound

• Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study

• HIVR4P 2024: Context of PrEP in Latin America

Treatment access

• Helsinki Declaration: 2024 edition upholds ethical access to treatment

• Gilead announces plans to support generic lenacapavir for low-income countries

mpox

• Confirmed mpox clade 1b case in Germany: risk remains low for EU/EEA

• Lack of tecovirimat activity against mpox clade 1

• Efficacy of MVA-BN vaccine: systematic review

• Mpox outbreak in Australia: half of cases had previously received a vaccine

• WHO situation report on mpox

Coinfections and complications

• Kidney transplants from HIV positive donors to HIV recipients

Treatment advocacy

• US NIAID updates HIV guide to person-centred language

On the web

• Long COVID essentials: link to online resources